GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SomaLogic Inc (NAS:SLGC) » Definitions » Piotroski F-Score

SomaLogic (SomaLogic) Piotroski F-Score : 2 (As of Apr. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is SomaLogic Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

SomaLogic has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for SomaLogic's Piotroski F-Score or its related term are showing as below:

SLGC' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 3
Current: 2

During the past 3 years, the highest Piotroski F-Score of SomaLogic was 3. The lowest was 2. And the median was 3.


SomaLogic Piotroski F-Score Historical Data

The historical data trend for SomaLogic's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SomaLogic Piotroski F-Score Chart

SomaLogic Annual Data
Trend Dec20 Dec21 Dec22
Piotroski F-Score
N/A N/A 3.00

SomaLogic Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 3.00 N/A N/A 2.00

Competitive Comparison of SomaLogic's Piotroski F-Score

For the Health Information Services subindustry, SomaLogic's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SomaLogic's Piotroski F-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, SomaLogic's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where SomaLogic's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Net Income was -49.251 + -34.202 + -24.772 + -22.157 = $-130.38 Mil.
Cash Flow from Operations was -26.608 + -43.045 + -26.237 + -21.365 = $-117.26 Mil.
Revenue was 18.829 + 20.379 + 20.468 + 22.048 = $81.72 Mil.
Gross Profit was 5.864 + 8.063 + 9.293 + 10.413 = $33.63 Mil.
Average Total Assets from the begining of this year (Sep22)
to the end of this year (Sep23) was
(688.244 + 647.374 + 614.24 + 585.746 + 565.048) / 5 = $620.1304 Mil.
Total Assets at the begining of this year (Sep22) was $688.24 Mil.
Long-Term Debt & Capital Lease Obligation was $2.76 Mil.
Total Current Assets was $494.11 Mil.
Total Current Liabilities was $27.78 Mil.
Net Income was -23.307 + -3.979 + -22.985 + -32.942 = $-83.21 Mil.

Revenue was 22.994 + 22.98 + 14.144 + 41.713 = $101.83 Mil.
Gross Profit was 12.531 + 11.328 + 7.067 + 30.043 = $60.97 Mil.
Average Total Assets from the begining of last year (Sep21)
to the end of last year (Sep22) was
(718.541 + 706.102 + 713.175 + 686.079 + 688.244) / 5 = $702.4282 Mil.
Total Assets at the begining of last year (Sep21) was $718.54 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $621.26 Mil.
Total Current Liabilities was $42.68 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

SomaLogic's current Net Income (TTM) was -130.38. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

SomaLogic's current Cash Flow from Operations (TTM) was -117.26. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep22)
=-130.382/688.244
=-0.18944154

ROA (Last Year)=Net Income/Total Assets (Sep21)
=-83.213/718.541
=-0.11580828

SomaLogic's return on assets of this year was -0.18944154. SomaLogic's return on assets of last year was -0.11580828. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

SomaLogic's current Net Income (TTM) was -130.38. SomaLogic's current Cash Flow from Operations (TTM) was -117.26. ==> -117.26 > -130.38 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=2.763/620.1304
=0.00445551

Gearing (Last Year: Sep22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep21 to Sep22
=0/702.4282
=0

SomaLogic's gearing of this year was 0.00445551. SomaLogic's gearing of last year was 0. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep23)=Total Current Assets/Total Current Liabilities
=494.105/27.781
=17.78571686

Current Ratio (Last Year: Sep22)=Total Current Assets/Total Current Liabilities
=621.26/42.675
=14.5579379

SomaLogic's current ratio of this year was 17.78571686. SomaLogic's current ratio of last year was 14.5579379. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

SomaLogic's number of shares in issue this year was 187.071. SomaLogic's number of shares in issue last year was 184.408. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=33.633/81.724
=0.41154373

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=60.969/101.831
=0.5987273

SomaLogic's gross margin of this year was 0.41154373. SomaLogic's gross margin of last year was 0.5987273. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep22)
=81.724/688.244
=0.11874277

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep21)
=101.831/718.541
=0.14171912

SomaLogic's asset turnover of this year was 0.11874277. SomaLogic's asset turnover of last year was 0.14171912. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+1+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

SomaLogic has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

SomaLogic  (NAS:SLGC) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


SomaLogic Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of SomaLogic's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


SomaLogic (SomaLogic) Business Description

Traded in Other Exchanges
N/A
Address
2945 Wilderness Place, Boulder, CO, USA, 80301
SomaLogic is a commercial-stage proteomics company. It operates as a protein biomarker discovery and clinical diagnostics company that develops slow off-rate modified aptamers, which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. The Somamers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development.
Executives
Alison Marie Roelke officer: Chief People Officer 900 INNOVATORS WAY, SIMI VALLEY CA 93065
Adam Taich officer: Interim CEO C/O SOMALOGIC, INC., 2945 WILDERNESS PLACE, BOULDER CO 80301
Ruben Gutierrez officer: General Counsel 6435 AVENIDA WILFREDO, LA JOLLA CA 92037
Kathy L Hibbs director C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
Jason Ryan director C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Thomas D. Carey director 8 PAIGE STREET, HINGHAM MA 02043
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Tycho Peterson director C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
Eli Casdin director 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Shaun M. Blakeman officer: Chief Financial Officer C/O CANTEL MEDICAL CORP., 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Anne H. Margulies director C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Richard A Post director 998 LACOSTA LANE, LANE TREE CO 80124
Charles M. Lillis director 13 CASTLE PINES DRIVE N, CASTLE ROCK CO 80108
Stephen Quake director C/O FLUIDIGM CORPORATION, 7000 SHORELINE COURT, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Robert Barchi director